Document:

Exhibit
10.8

 

Pine Technology Acquisition Corp.

260 Lena Drive

Aurora, OH 44202

 

[DATE]

 

Peel
Acquisition Company II, LLC

5423 17th Avenue

Brooklyn, NY 11204

 

		Re:	Administrative
Services Agreement

 

Ladies
and Gentlemen:

 

This
letter agreement by and between Pine Technology Acquisition Corp., a Delaware corporation (the “Company”) and Peel Acquisition
Company II, LLC, a Delaware limited liability corporation (the “Services Provider”), dated as of the
date hereof, will confirm our agreement that, commencing on the date that securities of the Company are first listed on the Nasdaq
Stock Market LLC (the “Listing Date”) and continuing until the earlier of the consummation by the Company
of an initial business combination and the Company’s liquidation (in each case as described in the Registration Statement
on Form S-1 (File No. 333-[•]) filed with the Securities and Exchange Commission) (such earlier date hereinafter
referred to as the “Termination Date”):

 

	 	1.	The
    Services Provider (and/or any of its affiliates designated by the Services Provider) shall make available to the Company,
    at the address of the Services Provider referred to above (or any successor location or other existing office locations of
    the Services Provider or any of its affiliates), office space and administrative and support services as may be reasonably
    requested by the Company. In exchange therefor, the Company shall pay to the Services Provider, on the first day of each month,
    the sum of $10,000 per month commencing on the Listing Date and continuing monthly thereafter until the Termination Date;
    and

 

	 	2.	The
    Services Provider hereby irrevocably waives any and all right, title, interest, causes of action and claims of any kind or
    nature whatsoever (each, a “Claim”) in or to, and any and all right to seek payment of any amounts
    due to it out of, the trust account established for the benefit of the public stockholders of the Company and into which substantially
    all of the proceeds of the Company’s initial public offering will be deposited (the “Trust Account”),
    and hereby irrevocably waives any Claim it presently has or may have in the future as a result of, or arising out of, this
    letter agreement, which Claim would reduce, encumber or otherwise adversely affect the Trust Account or any monies or other
    assets in the Trust Account, and further agrees not to seek recourse, reimbursement, payment or satisfaction of any Claim
    against the Trust Account or any monies or other assets in the Trust Account for any reason whatsoever.

 

This
letter agreement constitutes the entire agreement and understanding of the parties hereto in respect of its subject matter and
supersedes all prior understandings, agreements, or representations by or among the parties hereto, written or oral, to the extent
they relate in any way to the subject matter hereof or the transactions contemplated hereby.

 

This
letter agreement may not be amended, modified or waived as to any particular provision, except by a written instrument executed
by all parties hereto.

 

No
party hereto may assign either this letter agreement or any of its rights, interests, or obligations hereunder without the prior
written approval of the other party, provided that the Services Provider may assign this letter agreement or any of its rights,
interests, or obligations hereunder to an affiliate without the prior written approval of the Company. Any purported assignment
in violation of this paragraph shall be void and ineffectual and shall not operate to transfer or assign any interest or title
to the purported assignee.

 

This
letter agreement constitutes the entire relationship of the parties hereto with respect to the subject matter described herein
and any litigation between the parties (whether grounded in contract, tort, statute, law or equity) shall be governed by and construed
in accordance with the laws of the State of New York.

 

This
letter agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original
but all of which together shall constitute one and the same letter agreement.

 

[Signature
page follows]

 

     

     

    

 

	 	Very
    truly yours,
	 	 
	 	PINE
TECHNOLOGY ACQUISITION CORP.
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

[Signature
Page to Administrative Services Agreement]

 

     

     

    

 

 

	AGREED
    TO AND ACCEPTED BY:	 
	 	 
	PEEL
    ACQUISITION COMPANY II, LLC	 
	 	 
	By:	 	 
	 	Name:	 
	 	Title:EX-4.2

 Exhibit 4.2 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT is made as of October 30, 2020 by and among Prometheus Biosciences, Inc., a Delaware corporation formerly known as Precision IBD, Inc. (the “Company”), and each of the investors listed on
SCHEDULE A hereto, each of which is referred to in this Agreement as an “Investor.” 

RECITALS 

A.    Certain of the Investors (the “Existing Investors”) hold shares of the Company’s
Series A Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”), Series B Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”) and/or Series C Preferred
Stock, par value $0.0001 per share (the “Series C Preferred Stock”) and possess registration rights, information rights, rights of first offer, and other rights pursuant to that certain Amended and Restated Investors’
Rights Agreement dated as of March 27, 2020, by and among the Company and such Existing Investors (the “Prior Agreement”). 

B.    The Existing Investors are holders of a majority of the Registrable Securities of the Company (as defined in
the Prior Agreement), and desire to amend and restate the Prior Agreement in its entirety and to accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Prior Agreement. 

C.    Certain of the Investors are parties to that certain Series D Preferred Stock Purchase Agreement dated as of
even date herewith, by and among the Company and such Investors (as the same may be amended from time to time, the “Purchase Agreement”), under which certain of the Company’s and such Investors’ obligations are
conditioned upon the execution and delivery of this Agreement.  
 NOW,
THEREFORE, the parties, intending to be legally bound, hereby agree as follows: 

1.    Definitions. For purposes of this Agreement: 

1.1    “Affiliate” means, with respect to any specified Person, any other Person who,
directly or indirectly, controls, is controlled by, or is under common control with such Person, including, without limitation, any general partner, managing member, director, officer or trustee of such Person, or any venture capital fund,
investment fund or registered investment company now or hereafter existing that is controlled by one or more general partners, managing members, investment advisers or investment advisers directly or indirectly owned or controlled by such Person, or
shares the same management company or investment adviser with such Person. 
 1.2    “Certificate of
Incorporation” means the Company’s Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time. 

1.3    “Common Stock” means shares of the Company’s common stock, par value $0.0001
per share. 
 1.4    “Competitor” means a Person engaged, directly or indirectly
(including through 

 
any partnership, limited liability company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in pharmaceutical research, development or
commercialization, but shall not include (i) Cedars-Sinai Medical Center, (ii) Nestlé Health Science US Holdings, Inc., Société des Produits Nestlé S.A., (iii) Point72 Asset Management, (iv) RTW
Investments, LP (“RTW”), or, in the case of (i)(iv), any of their respective Affiliates or (v) any financial investment firm or collective investment vehicle that, together with its Affiliates, (a) holds less than
thirty percent (30%) of the outstanding equity of any Competitor or, (b) holds more than thirty percent (30%) of the outstanding equity of any Competitor but does not (either directly or through any of its Affiliates) have a right to designate
any members of the board of directors of such Competitor. 
 1.5    “Damages” means any
loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect
thereof) arises out of or is based upon (a) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein
or any amendments or supplements thereto; (b) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (c) any violation or alleged
violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities
law. 
 1.6    “Derivative Securities” means any securities or rights convertible into,
or exercisable or exchangeable for (in each case, directly or indirectly), Common Stock, including options and warrants. 

1.7    “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules
and regulations promulgated thereunder. 
 1.8    “Excluded Registration” means
(a) a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (b) a registration relating to an SEC Rule 145 transaction; (c) a
registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (d) a registration in which the only Common
Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. 

1.9    “Form S-1” means such form under the
Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 

1.10    “Form S-3” means such form under the
Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC.

 1.11    “GAAP” means generally accepted accounting principles in the United States.

 1.12    “Holder” means any Investor owning Registrable Securities. 

1.13    “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent,
grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law,
brother-in-law, or sister-in-law, including adoptive relationships, of a natural person
referred to herein. 

  
 2 

 1.14    “Initiating Holders” means,
collectively, Holders who properly initiate a registration request under this Agreement. 

1.15    “IPO” means the Company’s first underwritten public offering of its Common
Stock under the Securities Act. 
 1.16    “Major Investor” means any Investor that,
individually or together with such Investor’s Affiliates, holds at least 9,000,000 shares of Common Stock issuable or issued upon conversion of the Preferred Stock (as adjusted for any stock split, stock dividend, combination or other
recapitalization or reclassification effected after the date hereof). 
 1.17    “New
Securities” means, collectively, equity securities of the Company or its subsidiaries, whether or not currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever
that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

1.18    “Person” means any individual, corporation, partnership, trust, limited liability
company, association or other entity. 
 1.19    “Preferred Stock” means collectively,
Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock. 

1.20    “Registrable Securities” means (a) the Common Stock issuable or issued upon
conversion of the Preferred Stock; (b) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, held by the Investors; (c) any Common Stock
issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses
(a) and (b) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Section 6.1, and
excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Section 2.13 of this Agreement. 

1.21    “Registrable Securities then outstanding” means the number of shares determined by
adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable
Securities. 
 1.22    “Restricted Securities” means the securities of the Company
required to bear the legend set forth in Section 2.12 hereof. 

1.23    “SEC” means the Securities and Exchange Commission. 

1.24    “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.25    “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.26    “Securities Act” means the Securities Act of 1933, as amended, and the rules and
regulations promulgated thereunder. 

  
 3 

 1.27    “Selling Expenses” means all
underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne
and paid by the Company as provided in Section 2.6. 
 1.28    “Series A
Preferred Stock” means shares of the Company’s Series A Preferred Stock, par value $0.0001 per share. 

1.29    “Series B Preferred Stock” means shares of the Company’s Series B Preferred
Stock, par value $0.0001 per share. 
 1.30    “Series C Preferred Stock” means shares of
the Company’s Series C Preferred Stock, par value $0.0001 per share. 
 1.31    “Series D
Preferred Director” means any director of the Company that the holders of record of Series D Preferred Stock are entitled to elect, exclusively and as a separate class, pursuant to the Certificate of Incorporation. 

1.32    “Series D Preferred Stock” means collectively, shares of the Company’s Series D-1 Preferred Stock, par value $0.0001 per share, and shares of the Company’s Series D-2 Preferred Stock, par value $0.0001 per share. 

2.    Registration Rights. The Company covenants and agrees as follows: 

2.1    Demand Registration. 

(a)    Form S-1 Demand. If at any time after the date that is five (5)
years after the date of this Agreement, the Company receives a request from Holders of a majority of the Registrable Securities then outstanding that the Company file a Form S-1 registration statement with
respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $10,000,000, then the Company shall (i) within ten (10) days after the date such request is
given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the
Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable
Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the
limitations of Section 2.1(c) and Section 2.3. 
 (b)    Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives from any Holder or Holders a request that the Company file a
Form S-3 registration statement with respect to outstanding Registrable Securities of such Holder or Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $5,000,000,
then the Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five
(45) days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in
such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of
Section 2.1(c) and Section 2.3. 

  
 4 

 (c)    Notwithstanding the foregoing obligations, if the Company
furnishes to Holders requesting a registration pursuant to this Section 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors
(the “Board”) it would be materially detrimental to the Company and its stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be
required to remain effective, because such action would (i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material
information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to
defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than ninety (90) days after the request of the Initiating Holders is
given for any registration pursuant to Section 2.1(a) or 2.1(b); provided, however, that the Company may not invoke this right more than once in any twelve (12) month period; and provided further
that the Company shall not register any securities for its own account or that of any other stockholder during such ninety-day period, other than an Excluded Registration. 

(d)    The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to
Section 2.1(a): (i) during the period starting with the date of filing of, and ending on a date that is one hundred eighty (180) days after the effective date of, a Company-initiated registration, provided, that
the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected two (2) registrations pursuant to
Section 2.1(a); or (iii) if within thirty (30) days of receipt of a request from any Holder or Holders pursuant to Section 2.1(a), the Company gives notice to such Holder or Holders of
the Company’s intention to make a public offering within one hundred twenty (120) days. The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(b):
(i) if within thirty (30) days of receipt of a request from any Holder or Holders pursuant to Section 2.1(b), the Company gives notice to such Holder or Holders of the Company’s intention to make a public offering
within ninety (90) days; or (ii) if the Company has effected two (2) registrations pursuant to Section 2.1(b) within the twelve (12) month period immediately preceding the date of such request. A
registration shall not be counted as “effected” for purposes of this Section 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders
withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Section 2.6, in which case such withdrawn
registration statement shall be counted as “effected” for purposes of this Section 2.1(d). 

2.2    Company Registration. If the Company proposes to register (including, for this purpose, a registration
effected by the Company for stockholders other than the Holders) any of its securities under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the Company shall, at
such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of
Section 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration
initiated by it under this Section 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses)
of such withdrawn registration shall be borne by the Company in accordance with Section 2.6  

2.3    Underwriting Requirements. 

  
 5 

 (a)    If, pursuant to Section 2.1, the
Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1, and the
Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include
such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided
herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in Section 2.4(e) enter into an underwriting agreement in customary form with the
underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Section 2.3, if the underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the
number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the
underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as
shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely
excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. 

(b)    In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant
to Section 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company
and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities,
requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the
Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If
the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders
in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in
accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event shall (i) the number of
Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the
offering be reduced below twenty percent (20%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination
described above and no other stockholder’s securities are included in such offering. For purposes of the provision in this Section 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited
liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired
members and any trusts for 

  
 6 

 
the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based
upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence. 

(c)    For purposes of Section 2.1, a registration shall not be counted as “effected”
if, as a result of an exercise of the underwriter’s cutback provisions in Section 2.3(a), fewer than fifty percent (50%) of the total number of Registrable Securities that Holders have requested to be included in such
registration statement are actually included. 
 2.4    Obligations of the Company. Whenever required under this
Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a)    prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its
commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period
of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be extended
for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any
registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day
period shall be extended for up to one hundred eighty (180) days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; 

(b)    prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus
used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c)    furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as
required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d)    use its commercially reasonable efforts to register and qualify the securities covered by such registration
statement under such other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to
do business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e)    in the event of any underwritten public offering, enter into and perform its obligations under an underwriting
agreement, in usual and customary form, with the underwriter(s) of such offering; 
 (f)    use its commercially
reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities
issued by the Company are then listed; 

  
 7 

 (g)    provide a transfer agent and registrar for all Registrable
Securities registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(h)    promptly make available for inspection by the selling Holders, any underwriter(s) participating in any disposition
pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the
Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable
to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i)    notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration
statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 

(j)    after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the
Company amend or supplement such registration statement or prospectus. 
 In addition, the Company shall ensure that, at all times after any
registration statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under
Rule 10b5-1 of the Exchange Act. 
 2.5    Furnish Information. It shall
be a condition precedent to the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such
information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.6    Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with
registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the
reasonable fees and disbursements, not to exceed $50,000 per registration, of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company
shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable
Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the
Registrable Securities agree to forfeit their right to one registration pursuant to Section 2.1(a) or Section 2.1(b), as the case may be; provided further that if, at the time of such
withdrawal, the Holders shall have learned of a material adverse change in the financial condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable
promptness after learning of such information, then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Section 2.1(a) or
Section 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of
Registrable Securities registered on their behalf. 

  
 8 

 2.7    Delay of Registration. No Holder shall have any right to
obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this
Section 2. 
 2.8    Indemnification. If any Registrable Securities are included in a
registration statement under this Section 2: 
 (a)    To the extent permitted by law, the
Company will indemnify and hold harmless each selling Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities
Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling
Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided,
however, that the indemnity agreement contained in this Section 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company,
which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished
by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration. 

(b)    To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless
the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any
underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each case only to the extent that such
Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each such
selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses
are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the
consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Sections 2.8(b) and
2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 

(c)    Promptly after receipt by an indemnified party under this Section 2.8 of notice of the
commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this
Section 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate
jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified
parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by

  
 9 

 
the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel
in such action. The failure to give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this
Section 2.8, to the extent that such failure materially prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that
it may have to any indemnified party otherwise than under this Section 2.8. 

(d)    Notwithstanding anything else herein to the contrary, the foregoing indemnity agreements of the Company and the
selling Holders are subject to the condition that, insofar as they relate to any Damages arising from any untrue statement or alleged untrue statement of a material fact contained in, or omission or alleged omission of a material fact from, a
preliminary prospectus (or necessary to make the statements therein not misleading) that has been corrected in the form of prospectus included in the registration statement at the time it becomes effective, or any amendment or supplement thereto
filed with the SEC pursuant to Rule 424(b) under the Securities Act (the “Final Prospectus”), such indemnity agreement shall not inure to the benefit of any Person if a copy of the Final Prospectus was furnished to the
indemnified party and such indemnified party failed to deliver, at or before the confirmation of the sale of the shares registered in such offering, a copy of the Final Prospectus to the Person asserting the loss, liability, claim, or damage in any
case in which such delivery was required by the Securities Act. 
 (e)    To provide for just and equitable
contribution to joint liability under the Securities Act in any case in which either (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8 but it
is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case,
notwithstanding the fact that this Section 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is
provided under this Section 2.8, then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in
such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or
expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue
statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and
opportunity to correct or prevent such statement or omission; provided, however, that, in any such case, (1) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities
offered and sold by such Holder pursuant to such registration statement, and (2) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person
who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Section 2.8(d), when combined with the amounts paid or payable by such
Holder pursuant to Section 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 

(f)    Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in
the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

  
 10 

 (g)    Unless otherwise superseded by an underwriting agreement entered
into in connection with the underwritten public offering, the obligations of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this
Section 2, and otherwise shall survive the termination of this Agreement. 
 2.9    Reports
Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration
or pursuant to a registration on Form S-3, the Company shall: 
 (a)    make and
keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b)    use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents
required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c)    furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to
the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the
IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form
S-3 (at any time after the Company so qualifies) and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any
such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies
to use such form). 
 2.10    Limitations on Subsequent Registration Rights. From and after the date of this
Agreement, the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that
would (a) allow such holder or prospective holder to include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the
extent that the inclusion of such securities will not reduce the number of the Registrable Securities of the Holders that are included or (b) allow such holder or prospective holder to initiate a demand for registration of any securities held
by such holder or prospective holder; provided that this limitation shall not apply to any additional Investor who becomes a party to this Agreement in accordance with Section 6.9. 

2.11    “Market Stand-off” Agreement. Each Holder hereby agrees
that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the registration by the Company of shares of its Common Stock or any other equity
securities under the Securities Act on a registration statement on Form S-1, and ending on the date specified by the Company and the managing underwriter, such period not to exceed one hundred eighty
(180) days in the case of the IPO: (a) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or

  
 11 

 
otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock
held immediately before the effective date of the registration statement for such offering or (b) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of
such securities, whether any such transaction described in clause (a) or (b) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Section 2.11
shall apply only to the IPO, shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, shall not apply to transactions relating to securities acquired in the IPO or open market transactions from and after the
IPO (provided that no such transaction is required to be, or is, publicly announced during the period described in the preceding sentence), and shall be applicable to the Holders only if all officers and directors and all stockholders individually
owning more than one percent (1%) of the Company’s outstanding Common Stock (after giving effect to the conversion into Common Stock of all outstanding Preferred Stock) are subject to the same restrictions. The underwriters in connection with
such registration are intended third-party beneficiaries of this Section 2.11 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to
execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Section 2.11 or that are necessary to give further effect thereto, in each case,
with such modifications as the underwriters and any Holder may mutually agree to. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Holders
subject to such agreements, based on the number of shares subject to such agreements 
 2.12    Restrictions on
Transfer. 
 (a)    The Preferred Stock and the Registrable Securities shall not be sold, pledged, or
otherwise transferred, and the Company shall not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions
are intended to ensure compliance with the provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take
and hold such securities subject to the provisions and upon the conditions specified in this Agreement. 

(b)    Each certificate, instrument or book entry representing (i) the Preferred Stock, (ii) the
Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall (unless
otherwise permitted by the provisions of Section 2.12(c)) be notated with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES
MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER,
A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 

  
 12 

 The Holders consent to the Company making a notation in its records and giving instructions to any transfer
agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Section 2.12. 

(c)    The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all
respects with the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed
transaction, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in
sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the
Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or
transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to
the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such
Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (1) in any transaction in compliance with SEC Rule 144 or
(2) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that each transferee agrees in writing to be subject to the terms of this
Section 2.12. Each certificate, instrument, or book entry representing the Restricted Securities transferred as above provided shall bear, except if such transfer is made pursuant to SEC Rule 144, the appropriate
restrictive legend set forth in Section 2.12(b), except that such certificate, instrument, or book entry shall not bear such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is
not required in order to establish compliance with any provisions of the Securities Act. 
 2.13    Termination of
Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Section 2.1 or Section 2.2 shall terminate upon the
earliest to occur of: (a) seven (7) years after the effective date of the Company’s Registration Statement filed in connection with the Company’s IPO, (b) at such time as Rule 144 or another similar exemption under the Securities
Act is available for the sale of all of such Holder’s shares without limitation during a three-month period without registration and (c) the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of
Incorporation. 
 3.    Information and Observer Rights. 

3.1    Delivery of Financial Statements. The Company shall deliver to each Major Investor, provided that the
Board has not reasonably determined that such Major Investor is a Competitor: 
 (a)    as soon as practicable,
but in any event within one hundred twenty (120) days after the end of each fiscal year of the Company, (i) an audited balance sheet as of the end of such year, (ii) audited statements of income and of cash flows for such year and
(iii) a statement of stockholders’ equity as of the end of such year, all such financial statements shall be prepared in accordance with GAAP, consistently applied, and setting forth in comparative form the figures for the previous fiscal
year, in reasonable detail. 

  
 13 

 (b)    as soon as practicable, but in any event within
forty-five (45) days after the end of each of the first three (3) quarters of each fiscal year of the Company, unaudited statements of income and of cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of
stockholders’ equity as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and
(ii) not contain all notes thereto that may be required in accordance with GAAP). 
 (c)    as soon as
practicable, but in any event within 45 days after the end of each quarter of each fiscal year of the Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for
shares of capital stock outstanding at the end of the applicable period, the Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price
applicable thereto, and the number of shares of issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity
ownership in the Company, and certified by the chief financial officer or chief executive officer of the Company as being true, complete, and correct. 

(d)    such other information relating to the financial condition, business, prospects, or corporate affairs of
the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Section 3.1 to provide information (i) that the Company
reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or (ii) the disclosure of which would adversely affect the
attorney-client privilege between the Company and its counsel. 
 If, for any period, the Company has any subsidiary whose accounts are consolidated with
those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated
subsidiaries.     
 3.2    Inspection. The Company shall permit each Major Investor, or any
of its authorized representatives, at such Major Investor’s expense (provided that the Board has not reasonably determined that such Major Investor is a Competitor), to visit and inspect the Company’s properties; examine its
corporate and financial records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that the
Company shall not be obligated pursuant to this Section 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an
enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

3.3    Observer Rights. As long as Eventide Asset Management, LLC (“Eventide”) or RTW, as the case
may be, owns shares of the Series D Preferred Stock it is purchasing under the Purchase Agreement (or an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of Eventide and RTW, respectively,
to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give each such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same
time and in the same manner as provided to such directors; provided, however, that each such representative shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any
information and to exclude any such representative from any meeting or portion thereof if 

  
 14 

 
access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a
conflict of interest, or if such Investor or its representative is a competitor of the Company. 
 3.4    Termination
of Information, Inspection and Observer Rights. The covenants set forth in Section 3.1, Section 3.2 and Section 3.3 shall terminate and be of no further force or
effect (a) immediately before the consummation of the IPO; (b) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act; or (c) upon a Deemed Liquidation Event,
as such term is defined in the Certificate of Incorporation, whichever event occurs first. 

3.5    Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose,
divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a
registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 3.5 by such Investor), (b) is or has been
independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach of any obligation of
confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain
their services in connection with monitoring its investment in the Company, if such person is bound by an ethical duty to keep such information confidential or such person agrees to be bound by the provisions of this
Section 3.5; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Section 3.5; (iii) to any
existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs such Person that such information is confidential and directs
such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, provided that the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent
of any such required disclosure. 
 4.    Rights to Future Stock Issuances. 

4.1    Right of First Offer. Subject to the terms and conditions of this Section 4 and
applicable securities laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each of the Investors. The Investors shall be entitled to apportion the right of first offer hereby granted
to them in such proportions as the Investors deem appropriate, among (a) the Investors, (b) Affiliates of the Investors and (c) the beneficial interest holders, such as limited partners, members or any other Person having
“beneficial ownership,” as such term is defined in Rule 13d3 promulgated under the Exchange Act, of any Investor (“Investor Beneficial Owners”); provided that, each such Affiliate or Investor Beneficial Owner
(x) is not a Competitor, unless such party’s purchase of New Securities is otherwise consented to by the Board, and (y) agrees to enter into this Agreement and each of the Voting Agreement and Right of First Refusal and Co-Sale Agreement of even date herewith among the Company, the Investors and the other parties named therein, as an “Investor” under each such agreement (provided that any Competitor shall
not be entitled to any rights as an Investor under Subsections 3.1, 3.2, and 4.1 hereof). 

4.2    Offer Notice. Prior to offering or selling any New Securities, the Company shall

  
 15 

 
give notice (the “Offer Notice”) to each Investor, stating (a) its bona fide intention to offer such New Securities, (b) the number of such New Securities to be
offered, and (c) the price and terms, if any, upon which it proposes to offer such New Securities. 

4.3    Election to Purchase. By notification to the Company within twenty (20) days after the Offer Notice is
given, each Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Investor
(including all shares of Common Stock then outstanding or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Investor) bears to the total
Common Stock of the Company then outstanding, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then outstanding. At the expiration of such twenty
(20) day period, the Company shall promptly notify each Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Investor’s failure to do
likewise. During the ten (10) day period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above,
up to that portion of the New Securities for which Investors were entitled to subscribe but that were not subscribed for by the Investors which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly)
upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion
and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this
Section 4 shall occur within the later of ninety (90) days after the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to this Section 4. 

4.4    Failure to Purchase. If all New Securities referred to in the Offer Notice are not elected to be purchased
or acquired as provided in this Section 4, the Company may, during the ninety (90) day period following the expiration of the period provided in Section 4.3, offer and sell the remaining
unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of
the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless
first reoffered to the Investors in accordance with this Section 4. 
 4.5    Exceptions to
Right of First Offer. The right of first offer in this Section 4 shall not be applicable to (a) Exempted Securities (as defined in the Certificate of Incorporation); (b) shares of Common Stock issued in the IPO;
and (c) transactions whereby Investors holding a majority of the Preferred Stock (including Investors holding a majority of the Series D Preferred Stock) and shares of Common Stock issued upon conversion of such Preferred Stock then held by the
Investors (the “Requisite Investors”) waive the rights granted by this Section 4 with respect to such transaction; provided that no Investor who shall have consented to such waiver shall purchase any
securities in such transaction or any related transaction. 
 4.6    Termination. The covenants set forth in this
Section 4 shall terminate and be of no further force or effect (a) immediately before the consummation of the IPO; (b) when the Company first becomes subject to the periodic reporting requirements of
Section 12(g) or 15(d) of the Exchange Act; or (c) upon a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first. 

  
 16 

 5.    Additional Covenants. 

5.1    Insurance. The Company shall use its commercially reasonable efforts to maintain, from financially sound and
reputable insurers, director and officer liability insurance in an amount and on terms and conditions satisfactory to the Board, until such time as the Board determines that such insurance should be discontinued. 

5.2    Proprietary Information and Inventions Agreements. Unless otherwise approved by the Board, the Company will
cause each former, current or future founder, employee, consultant or officer of the Company to enter into a Confidential Information Agreement (as defined in the Purchase Agreement). 

5.3    Employee Stock. Unless otherwise approved by the Board or the compensation committee of the Board all future
employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as
applicable, providing for (i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares vesting
in equal monthly installments over the following thirty-six (36) months, and (ii) a market stand-off provision substantially similar to that in
Section 2.11. In addition, unless otherwise approved by the Board, the Company shall retain a “right of first refusal” on employee transfers until the Company’s IPO and shall have the right to repurchase
unvested shares at cost upon termination of employment of a holder of restricted stock. 
 5.4    [Reserved.]  
 5.5    Board Matters. Unless otherwise determined by the
vote of a majority of the directors then in office, the Board shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the nonemployee directors for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board. All non-employee directors
will be compensated uniformly for service on the Board, except for any grant of stock options or other equity to the independent director which is approved by the Board or the compensation committee of the Board.     

5.6    Matters Requiring Preferred Director Approval. During such time or times as the holders of Series D
Preferred Stock are entitled to elect a Series D Preferred Director and such seat is filled, the Company hereby covenants and agrees with each of the Investors that it shall not, without approval of the Board, which approval must include the
affirmative vote of at least one of the Series D Preferred Directors:  
 (a)    make, or permit any
subsidiary to make, any loan or advance to, or own any stock or other securities of, any subsidiary or other corporation, partnership, or other entity unless it is wholly owned by the Company; 

(b)    make, or permit any subsidiary to make, any loan or advance to any Person, including, without limitation,
any employee or director of the Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan approved by the Board; 

  
 17 

 (c)    guarantee, directly or indirectly, or permit any
subsidiary to guarantee, directly or indirectly, any indebtedness except for trade accounts of the Company or any subsidiary arising in the ordinary course of business; 

(d)    make any investment inconsistent with any investment policy approved by the Board; 

(e)    incur any aggregate indebtedness in excess of $500,000 that is not already included in the Company’s
budget approved by the Board, other than trade credit incurred in the ordinary course of business; 

(f)    change the principal business of the Company, enter new lines of business, or exit the current line of
business; 
 (g)    sell, assign, exclusively license, pledge, or encumber material technology or intellectual
property of the Company, other than licenses granted in the ordinary course of business; or 
 (h)    enter into
any corporate strategic relationship involving the payment, contribution, or assignment by the Company or to the Company of money or assets greater than one million dollars ($1,000,000). 

5.7    Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges
into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the
obligations of the Company with respect to indemnification of members of the Board as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, its Certificate of Incorporation, or elsewhere,
as the case may be. 
 5.8    Right to Conduct Activities. The Company hereby agrees and acknowledges
that certain Investors are professional investment funds, and as such invest in numerous portfolio companies, some of which may be deemed competitive with the Company’s business (as currently conducted or as currently propose to be
conducted). The Company hereby agrees that, to the extent permitted under applicable law, each such Investor shall not be liable to the Company for any claim arising out of, or based upon, (i) the investment by either such Investor in any
entity competitive with the Company, or (ii) actions taken by any partner, officer or other representative of such Investor to assist any such competitive company, whether or not such action was taken as a member of the board of directors of
such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) any of the Investors from liability associated with the unauthorized
disclosure of the Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company. 

5.9    FCPA. The Company represents that it shall not (and shall not permit any of its subsidiaries or affiliates
or any of its or their respective directors, officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or make any payment to, or otherwise contribute any item of value to, directly or indirectly, to
any third party, including any Non-U.S. Official (as (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”)), in each case, in violation of
the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further represents that it shall (and shall cause each of its subsidiaries 

  
 18 

 
and affiliates to) cease all of its or their respective activities, as well as remediate any actions taken by the Company, its subsidiaries or affiliates, or any of their respective directors,
officers, managers, employees, independent contractors, representatives or agents in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. Upon request, the Company agrees to provide responsive
information and/or certifications concerning its compliance with applicable anti-corruption laws. The Company shall promptly notify each Investor if the Company becomes aware of any Enforcement Action (as defined in the Purchase Agreement). The
Company shall, and shall cause any direct or indirect subsidiary or entity controlled by it, whether now in existence or formed in the future, to comply with the FCPA. The Company shall use its best efforts to cause any direct or indirect
subsidiary, whether now in existence or formed in the future, to comply in all material respects with all applicable laws. 

5.10    Relinquished Voting Rights. Notwithstanding anything to the contrary set forth in the Certificate of
Incorporation, the Company’s Bylaws, applicable law or elsewhere, the Company and the Investors hereby acknowledge and agree that at any time, from time to time, when Nestlé Health Science US Holdings, Inc., Société des
Produits Nestlé S.A. and any of their respective Affiliates that is or becomes a Holder (collectively, the “Nestlé Holders”) collectively hold twenty percent (20%) or more of the fully diluted capital stock of
the Company, the Nestlé Holders automatically, and without any further action required by any Person, do hereby voluntarily relinquish, and shall not attempt to assert or exercise under any circumstance, any voting rights with respect to any
Registrable Securities or other equity securities of the Company held by any Nestlé Holder, in each such case except for any voting rights set forth in Section 3.3 of Article IV(B) of the Certificate of Incorporation (which voting
rights, for the avoidance of doubt, are not being relinquished and can be freely exercised by any Nestlé Holder, as and when applicable); provided, however, that (a) for the avoidance of doubt, this
Section 5.10 shall have no force or effect during any period in which the Nestlé Holders collectively hold less than twenty percent (20%) of the fully diluted capital stock of the Company and (b) this
Section 5.10 shall not apply to any transferee of any Registrable Securities or other equity securities of the Company held by any Nestlé Holder. 

5.11    Termination of Covenants. The covenants set forth in this Section 5, except for
Section 5.5 and Section 5.10, shall terminate and be of no further force or effect (a) immediately before the consummation of the IPO, (b) when the Company first becomes subject to the
periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (c) upon a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first. 

6.    Miscellaneous. 

6.1    Successors and Assigns. The rights under this Agreement may be assigned (but only with all related
obligations) by a Holder to a transferee of Registrable Securities that (a) is an Affiliate of a Holder; (b) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s
Immediate Family Members; or (c) after such transfer, holds at least 1,000,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, stock combinations, and other recapitalizations); provided,
however, that (i) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred;
and (ii) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Section 2.11. For the purposes of
determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a
trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that all transferees who would not qualify individually for
assignment of rights shall have a single attorney-in-fact for the purpose of exercising any 

  
 19 

 
rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and
permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or
liabilities under or by reason of this Agreement, except as expressly provided herein. 
 6.2    Governing Law.
This Agreement and any controversy arising out of or relating to this Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware, without regard to conflict of law principles that would result in the
application of any law other than the laws of the State of Delaware. 
 6.3    Counterparts. This Agreement may
be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic
signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all
purposes. 
 6.4    Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience
only and are not to be considered in construing or interpreting this Agreement. 
 6.5    Notices. All notices
and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or: (a) personal delivery to the party to be notified; (b) when sent, if sent by
electronic mail or facsimile during the recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (c) five (5) days after having been sent by registered or certified
mail, return receipt requested, postage prepaid; or (d) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day
delivery, with written verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth on Schedule A hereto, or to the principal office of the Company and to the
attention of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or address as subsequently modified by written notice given in accordance with this Section 6.5. If notice is
given to the Company, it shall be sent to Prometheus Biosciences, Inc., 9410 Carroll Park Drive, San Diego, CA 92121, Attention: Mark McKenna; and a copy (which shall not constitute notice) shall also be sent to Latham & Watkins LLP, 12670
High Bluff Drive, San Diego, CA 92130, Attention: Cheston J. Larson. 
 6.6    Amendments and Waivers. Any term
of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of (i) the Company and
(ii) the Requisite Investors; provided, however that the Company may in its sole discretion waive compliance with Section 2.12(c) (and the Company’s failure to object promptly in writing after notification
of a proposed assignment allegedly in violation of Section 2.12(c) shall be deemed to be a waiver); and provided further that any provision hereof may be waived by any waiving party on such party’s own behalf,
without the consent of any other party. Notwithstanding the foregoing, this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor,
unless such amendment, termination, or waiver applies to all Investors in the same fashion (provided that, in the event that the provisions of Section 4 are waived with respect to a particular transaction, if any Major
Investor exercises its right under Section 4, the other Major Investors shall be entitled to participate in such transaction on a pro rata basis, unless the provisions of Section 4 have

  
 20 

 
been waived by the holders of a majority of the outstanding shares of Preferred Stock then held by the nonparticipating Major Investors (on an as-converted
basis). The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in
accordance with this Section 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any
one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. 

6.7    Severability. In case any one or more of the provisions contained in this Agreement is for any reason held
to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so
that it will be valid, legal, and enforceable to the maximum extent permitted by law. 
 6.8    Aggregation of
Stock. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as
among themselves in any manner they deem appropriate. 
 6.9    Additional Investors. Notwithstanding anything to
the contrary contained herein, if the Company issues additional shares of Series D Preferred Stock after the date hereof, whether pursuant to the Purchase Agreement or otherwise, any purchaser of such shares of Series D Preferred Stock may become a
party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be
required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. 

6.10    Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and
entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. 

6.11    Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction
of the state courts of Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to
commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of Delaware or the United States District Court for the District of Delaware, and (c) hereby waive, and agree not to assert, by
way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that
the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court.    

 6.12    WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE
OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE 

  
 21 

 
ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT
LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO
ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL
COUNSEL. 
 6.13    Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to
any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or
acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All
remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

6.14    Acknowledgment. The Company acknowledges that the Investors are in the business of venture capital
investing and therefore review the business plans and related proprietary information of many enterprises, including enterprises which may have products or services which compete directly or indirectly with those of the Company. Nothing in this
Agreement shall preclude or in any way restrict the Investors from investing or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the Company. 

6.15    Amendment and Restatement of Prior Agreement; Waiver of Right of First Offer. Upon execution of this
Agreement by the Company and Existing Investors holding a majority of the Registrable Securities under the Prior Agreement, the Prior Agreement shall thereafter be of no further force and effect and is hereby amended in its entirety and restated
herein, and all provisions of rights granted and covenants made in the Prior Agreement are hereby waived, released and superseded in their entirety and shall have no further force or effect including, without limitation, all rights and any notice
period associated therewith otherwise applicable to the transactions contemplated by the Purchase Agreement. 
 [SIGNATURE
PAGES FOLLOW] 

  
 22 

 IN WITNESS WHEREOF, the parties have
executed this Agreement as of the date first written above. 
 COMPANY: 

PROMETHEUS BIOSCIENCES, INC. 
  

			
	          By:	 	   /s/ Mark McKenna

			
	          Name: Mark McKenna
	          Title: President and CEO

 SIGNATURE PAGE – AMENDED AND
RESTATED INVESTORS RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have
executed this Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	NESTLÉ HEALTH SCIENCE US HOLDINGS, INC.
		
	By:	 	 /s/ James Pepin

			
	Name: James Pepin
	Title: President

 SIGNATURE PAGE – AMENDED AND
RESTATED INVESTORS RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have
executed this Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
		
	By:	 	 /s/ Claudio Kuoni

			
	Name: Claudio Kuoni
	Title: General Counsel NHSc

 SIGNATURE PAGE – AMENDED AND
RESTATED INVESTORS RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have
executed this Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	CEDARS-SINAI MEDICAL CENTER
		
	By:	 	 /s/ James D. Laur

			
	Name: James D. Laur
	Title: Vice President, Intellectual Property

  

			
	CEDARS-SINAI MEDICAL CENTER
		
	By:	 	 /s/ Edward M. Prunchunas

			
	Name: Edward M. Prunchunas
	Title: Executive Vice President and CFO

 SIGNATURE PAGE – AMENDED AND
RESTATED INVESTORS RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have
executed this Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	LIFE VENTURES 1 LP
		
	By:	 	 /s/ Douglas F. Wall

			
	Name: Douglas F. Wall
	Title: Managing Director

 SIGNATURE PAGE – AMENDED AND
RESTATED INVESTORS RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have
executed this Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	LIFE VENTURES II LP
		
	By:	 	 /s/ Douglas F. Wall

			
	Name: Douglas F. Wall
	Title: Managing Director

 SIGNATURE PAGE – AMENDED AND
RESTATED INVESTORS RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have
executed this Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	GLENN HOLDINGS, L.P.
		
	By:	 	 /s/ Scott L. Glenn

			
	Name: Scott L. Glenn
	Title: General Partner

 SIGNATURE PAGE – AMENDED AND
RESTATED INVESTORS RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the
parties have executed this Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	ROLF J. BENIRSCHKE AND MARY P. BENIRSCHKE FAMILY TRUST DATED JULY 16, 1990
		
	By:	 	 /s/ Rolf J. Benirschke

	Name: Rolf J. Benirschke
	Title: Trustee

 SIGNATURE PAGE – AMENDED AND
RESTATED INVESTORS RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the
parties have executed this Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	MUTUAL FUND SERIES TRUST, ON BEHALF OF EVENTIDE HEALTHCARE & LIFE SCIENCES FUND
		
	By:	 	 /s/ Erik Naviloff

			
	Name:	 	Erik Naviloff
	Title:	 	Officer

 SIGNATURE PAGE – AMENDED AND
RESTATED INVESTORS RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the
parties have executed this Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	CORMORANT PRIVATE HEALTHCARE FUND III, LP

 
			
		
	By:	 	Cormorant Private Healthcare GP, LLC

 
			
		
	By:	 	 /s/ Bihua Chen

 

			
	Name: Bihua Chen
	Title:   Managing Member
	
	CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP

 
			
		
	By:	 	Cormorant Global Healthcare GP, LLC

 
			
		
	By:	 	 /s/ Bihua Chen

 

			
	Name: Bihua Chen
	Title:   Managing Member
	
	CRMA SPV, L.P.

 
			
		
	By:	 	Cormorant Asset Management, LP

 
			
		
	By:	 	 /s/ Bihua Chen

 

			
	Name: Bihua Chen
	Title:   Attorney-in-fact

 SIGNATURE PAGE – AMENDED AND
RESTATED INVESTORS RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the
parties have executed this Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	COWEN HEALTHCARE INVESTMENTS III LP
	
	By: Cowen Healthcare Investments III GP LLC, its general partner
		
	By:	 	 /s/ Kevin Raidy

			
	Name:	 	Kevin Raidy
	Title:	 	Managing Partner
	
	CHI EF III LP
	
	By: Cowen Healthcare Investments III GP LLC, its General Partner

 
			
		
	By:	 	 /s/ Kevin Raidy

			
	Name:	 	Kevin Raidy
	Title:	 	Managing Partner

 SIGNATURE PAGE – AMENDED AND
RESTATED INVESTORS RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the
parties have executed this Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	IRVING INVESTORS PRIVATES OSC XXI, LLC
		
	By:	 	 /s/ Jeremy Abelson

			
	Name:	 	Jeremy Abelson
	Title:	 	Manager

 SIGNATURE PAGE – AMENDED AND
RESTATED INVESTORS RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the
parties have executed this Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

 
			
		
	By:	 	 /s/ James H. Mannix

			
	Name: James H. Mannix
	Title: Chief Operating Officer

 SIGNATURE PAGE – AMENDED AND
RESTATED INVESTORS RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the
parties have executed this Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	POINT72 BIOTECH PRIVATE INVESTMENTS, LLC
		
	By:	 	 /s/ Vincent Tortorella

	Name: Vincent Tortorella
	Title: Authorized Signatory

 SIGNATURE PAGE – AMENDED AND
RESTATED INVESTORS RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the
parties have executed this Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	RTW MASTER FUND, LTD.

 
			
		
	By:	 	/s/ Roderick Wong, M.D.

 
			
	Name: Roderick Wong, M.D.
	Title: Director
	
	RTW INNOVATION MASTER FUND, LTD.

 
			
		
	By:	 	/s/ Roderick Wong, M.D.

 
			
	Name: Roderick Wong, M.D.
	Title: Director
	
	RTW VENTURE FUND LIMITED
	
	By: RTW Investments, LP, its Investment Manager

 
			
		
	By:	 	/s/ Roderick Wong, M.D.

 
			
	Name: Roderick Wong, M.D.
	Title: Managing Partner

 SIGNATURE PAGE – AMENDED AND
RESTATED INVESTORS RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the
parties have executed this Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	ASCEND GLOBAL INVESTMENT FUND SPC- STRATEGIC SEGREGATED PORTFOLIO
		
	By:	 	 /s/ Halim Susanto

			
	Name:	 	Halim Susanto
	Title:	 	Director

  

 SCHEDULE A 

INVESTORS 
  

	
	 NAME

	Richard and Donna Baldridge Family Trust dtd Jan 29, 2008
	
	Merepoint Holdings, LLC
	
	 Rolf J. Benirschke and Mary P.
 Benirschke
Family Trust dated July 16, 1990

	
	Cedars-Sinai Medical Center
	
	Mike Dee
	
	 IRA Resources, Inc. FBO: Bradley Davis
 Foltz
IRA 35-37634

	
	Kathy May
	
	Glenn Holdings, L.P.
	
	Harlan and Debra Jacobs Family Trust dated September 17, 1999
	
	Christopher D. Hazuka, J.D., Ph.D.
	
	 The Entrust Group FBO Richard Jaffe
 IRA
7230004599

	
	Jay S. Johnson Revocable Trust

	
	 NAME

	Cheston J. Larson
	
	 Pensco Trust Company Custodian FBO
 Gary Levine
Roth IRA

	
	 Mahlberg Family Trust
 Barry
Mahlberg

	
	 Mossy Family Trust, UTD 6/30/05, Peter
 B.
Mossy, TTEE, Sandra M Mossy,
 TTEE

	
	Christopher Paben
	
	Kyle Paben
	
	Brian Pidgeon
	
	Life Ventures 1 LP
	
	VP Company Investments 2018, LLC
	
	IRAR Trust: Eric Joseph Zimmer IRA 3537926

	
	 NAME

	Ascend Global Investment Fund SPC – Strategic Segregated Portfolio
	
	Proehl Investment Ventures LLC
	
	Tadataka Yamada
	
	Life Ventures II, LP
	
	Twomey Family Investments, LLC
	
	 Christopher J. Twomey and Rebecca J.
 Twomey
Family Trust U.T.D. September 20, 2002

	
	WS Investment Company, LLC (2019A)
	
	WS Investment Company, LLC (20A)
	
	Dixon Family Trust

	
	 NAME

	Nestlé Health Science US Holdings, Inc.
	
	Société des Produits Nestlé S.A.
	
	Lord Wilmore Partners LLC.
	
	 Mutual Fund Series Trust, On Behalf Of
 Eventide
Healthcare & Life Sciences
 Fund

	
	RTW Master Fund, Ltd.
	
	RTW Innovation Master Fund, Ltd.
	
	RTW Venture Fund Limited
	
	Perceptive Life Sciences Master Fund, Ltd.
	
	Cowen Healthcare Investments III LP

	
	 NAME

	CHI EF III LP
	
	 Point72 Biotech Private Investments,

LLC

	
	Cormorant Private Healthcare Fund III, LP
	
	Cormorant Global Healthcare Master Fund, LP
	
	CRMA SPV, L.P.
	
	Irving Investors Privates OSC XXI, LLC

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00321-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00321-of-00352.parquet"}]]